AWH News and Press, Aspira Women's Health Inc. From 03/22/23

2023-03-22 22:49:01 ET Aspira Women's Health Inc. (AWH) Q4 2022 Earnings Conference Call March 22, 2023 16:30 ET Company Participants Nicole Sandford - President & Chief Executive Officer Ryan Phan - Chief Scientific Officer & Chief Operating Officer Marl...

2023-03-22 16:29:29 ET Aspira Women’s Health press release ( NASDAQ: AWH ): Q4 GAAP EPS of -$0.04 beats by $0.03 . Revenue of $2.15M (+16.2% Y/Y) misses by $0.1M . As of December 31, 2022, Aspira had $13.6 million in cash and short-term investments. Cash...

2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuite SM volume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call ...

AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the...

AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced that one of the nation’s top national health insurance companies with over 80 million live...

Aspira Women’s Health ( NASDAQ: AWH ) sees preliminary testing volume during the fourth quarter of 2022 of 5,643, an increase of 18 % compared to the fourth quarter of 2021 . The number of OvaSuite SM tests performed increased 23% to 21,424 tests during the year end...

Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results consistent with previously provided cash utilization guidance for the fourth quarter and full year of 2022 Further reduced staff t...

Provides clinical validation for the use of OvaWatch SM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses Paper published in the peer-reviewed journal, Frontiers in Medicine AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- As...

Expanded Medicare coverage for multi-marker testing, including Ova1Plus ® and OvaWatch SM , through the 2023 Omnibus Spending Bill Granted a new PLA Code for OvaWatch by the American Medical Association Expanded Medicaid coverage adding another 5 sta...

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the commercial launch of OvaWatch SM , a new non-invasive blood-based test for the ...